2017-10-11 19:20:44 UTC

Duration of Hepatitis C Virus Therapy

Oct. 11, 2017

Shorter duration therapy reduces treatment costs and may also improve adherence. How short can therapy be and who would qualify?

Guidelines for the treatment of chronic hepatitis C virus (HCV) do not encourage treatment for less than 12 weeks. Benjamin Emmanuel, MPH, Eleanor M. Wilson, MD, and Shyam Kottilil, MD, PhD, explain in AGA Perspectives that there is mounting evidence that many patients can achieve sustained virologic response with only eight weeks of treatment. The shorter duration therapy substantially reduces treatment costs and may also improve adherence as adherence tends to decrease as therapy duration increases. 

The authors recommend further exploration into shorter HCV therapy in target populations to address some of the issues that may arise, such as optimal retreatment strategies and the emergence of resistance-associated variants. 

Read the full article in AGA Perspectives.

More on Hepatitis C

Building Foundations Among Payers & Providers for Collaborative Care in HCV & HIV

Dec. 7, 2017

In this video, leading experts in HCV, HIV, and managed care engage in a crossfire panel discussion on key challenges, considerations and solutions for improving patient management, and appropriate access to HCV and HIV therapies.

Translating Basic Science Into Clinical Application

Dec. 7, 2017

The CMGH editors summarize five recently accepted studies in four sentences or less.

Experts Update HCV Treatment and Care Guidelines

Nov. 9, 2017

Revision adds newly approved treatments and recommendations for special populations.